CELLSEARCH Circulating Tumor Cell Test
Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CELLSEARCH® CTC Test, which allows for an assessment of patient prognosis.
Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CELLSEARCH® CTC Test.
The CELLSEARCH® Circulating Tumor Cell (CTC) Test is the only technology cleared by the FDA. In order to be cleared by the FDA, Liu says, the CELLSEARCH test met metrics for being reproducible and user-friendly.
Clinical Pearls
From a single tube of the patient's blood, the number of CTCs are counted in an automated and reproducible way. The number of CTCs can be anywhere from zero to tens or hundreds of thousands, Liu says, though the absolute number is not what matters. Patients with fewer than five CTCs have a favorable prognosis, while greater than or equal to five is unfavorable. The CELLSEARCH test allows for an assessment of patient prognosis and is predictive of progression-free survival and overall survival.
- CELLSEARCH is the only FDA-cleared technology to test for circulating tumor cells
- The test allows for an assessment of patient prognosis and is predictive of PFS and OS
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
